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INTRODUCTION
Oncologic patients often present to the hospital with nonspecific 
symptoms such as nausea, vomiting, and fatigue. These symptoms 
could be secondary to a life-threatening condition such as adrenal 
insufficiency. Tumor burden,1-4 radiation therapy,5-8 and intracranial 
metastases9-12 represent potential etiologies in the oncologic patient 
presenting with adrenal insufficiency. Therefore, it is important to 
consider both primary and secondary adrenal insufficiency in the 
initial differential diagnosis. 
Given that over 90% of the adrenal glands must be compromised 
to manifest as primary insufficiency,4 tumor burden represents a 
rare2 but clinically relevant manifestation that has been well-docu-
mented in case reports.1 This phenomenon has a reported incidence 
ranging between 1.1% and 33%.2-4 Stereotactic body radiation therapy 
(SBRT) is an emerging field that allows for more finely targeted and 
less toxic treatment than has been previously available for adrenal 
metastases.5-7,13-16 However, particularly in patients that receive 
bilateral treatment, primary adrenal insufficiency is a documented 
toxicity6-8 of which one retrospective review5 estimated an incidence 
as high as 16%.
Finally, intracranial metastases affecting pituitary function must 
be considered in oncologic patients presenting with signs and symp-
toms of adrenal insufficiency. Anterior pituitary insufficiency was the 
third most common manifestation of symptomatic pituitary manifes-
tations in one review, accounting for 23.6% of total cases.11 
 We report a female patient with past medical history significant 
for metastatic breast cancer status-post bilateral SBRT to the adrenal 
glands who presented with symptoms of adrenal insufficiency. 
Although there was a primary concern for primary adrenal insuffi-
ciency at time of initial presentation, she was found to have anterior 
pituitary insufficiency which led to a new diagnosis of intracranial 
metastases.
CASE REPORT
The patient was a 65-year-old woman with a history of infiltrating 
ductal carcinoma (IDC) of the left breast initially diagnosed in 2012. 
At that time, she was treated with modified radical mastectomy (4/25 
axillary lymph nodes), prophylactic right mastectomy, and adjuvant 
chemo-radiation which was completed in 2013. She was taking adju-
vant anastrozole and was being followed with surveillance imaging 
when a computed tomography (CT) scan in late 2019 indicated that 
she had a new suspicious pulmonary nodule. A follow-up positron 
emission tomography scan showed bilateral adrenal hyperactivity. 
She had a biopsy of her right adrenal gland which showed adenocar-
cinoma consistent with metastatic recurrence of her primary breast 
cancer. She underwent therapeutic SBRT to the left lung (50 Gy in 5 
fractions), right adrenal (45 Gy in 5 fractions), and left adrenal (40 
Gy in 5 fractions) which were completed during the summer of 2019.
In the fall of 2019, the patient presented to the emergency depart-
ment for intractable nausea and vomiting that she related to the start 
of her adrenal radiation treatments during the summer. Her admis-
sion labs were significant for hyponatremia (130, ref 137-147 mmol/l), 
hypokalemia 3.1 (3.5-5.1 mmol/l), hyperglycemia 235 (70-100 mg/
dl), and low random cortisol 0.9 (ref: 5-20 mcg/dl). 
Given her history, the major consideration at time of presenta-
tion was primary adrenal insufficiency secondary to recent bilateral 
adrenal SBRT. However, her adrenocorticotropic hormone (ACTH), 
drawn in the emergency department prior to initiation of systemic 
steroids, later came back low at 2 (7-63 pg/dl), suggestive instead of a 
secondary etiology. Her thyroid stimulating hormone was low normal 
0.85 (0.35-5.00 mcu/ml) in the setting of low free thyroxine (FT4) 
0.3 (0.6-1.6 ng/dl). A follicle-stimulating hormone level of 0.9 (27-153 
mu/ml) and luteinizing hormone of less than 0.2 (11-64 mu/ml) also 
were low, indicating pituitary insufficiency.
A brain magnetic resonance image with contrast showed numer-
ous (> 10) parenchymal intracranial metastases, as well as a 1.4 x 1.1 
x 0.9 cm irregular enhancing mass involving the hypothalamus, pitu-
itary, and infundibulum. She was treated initially with stress dose 
steroids which were transitioned to dexamethasone after the dis-
covery of vasogenic edema due to brain metastases. Her presenting 
symptoms rapidly resolved with adrenal replacement therapy and 
thyroid replacement. She was started on whole brain radiation prior 
to discharge.
DISCUSSION
Given our patient’s history of bilateral radiation treatments, radi-
ation-induced primary adrenal insufficiency was high on the initial 
differential. Surgery remains the standard of care for adrenal metas-
tases.5 More recently, stereotactic external-beam radiation therapy 
(SBRT) has emerged as an alternative option for local control in 
patients with limiting comorbidities.5-7,13 SBRT typically is well toler-
ated with few significant toxicities, likely due to its ability to precisely 
target areas of interest.14-16 Toxicities in these patients include nausea, 
vomiting, diarrhea, and fatigue.17,18 Few studies specifically examined 
SBRT-related adrenal toxicity, though it has been reported in several 
case series.6-8 The incidence of adrenal insufficiency in patients with 
bilateral treatment was reported to be 16% (n = 30).5 Due to the lack 
of available data, it is difficult to establish a dose threshold or time 
course. There is, however, a well-described connection between 
primary insufficiency and tumor burden itself.1 There potentially 
could be a mechanistic role for radiation treatments serving to exac-
erbate already reduced functional reserve in patients such as ours.7
The final diagnosis in our patient was anterior pituitary insuffi-
ciency presenting with adrenal insufficiency secondary to metastatic 
IDC. Breast and lung cancer are the most common primary tumors to 
metastasize to the pituitary, of which the majority are clinically silent.9 
Diabetes insipidus and panhypopituitarism are the most common 
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presentations of symptomatic pituitary metastasis.10 There is a pre-
dilection of metastases to the posterior pituitary; this is thought to be 
due to its rich blood supply from the systemic circulation (as opposed 
to the more limited hypophyseal circulation supplying the anterior 
pituitary).10,12 When discovered, treatment is focused on targeted 
therapy of the primary cancer, surgical resection, radiation therapy, 
and/or intrathecal chemotherapy.10 While prognosis is dependent 
upon the nature of the primary malignancy and extent of metastasis, 
cases by this point are generally systemic and aggressive; prognosis 
is poor.11
In this case, the importance of both ACTH and cortisol levels being 
drawn prior to the empiric initiation of corticosteroid treatment for 
adrenal insufficiency could not be understated. It is possible that, in 
the absence of an available ACTH level or other localizing symptoms, 
radiation-induced insufficiency would have been presumed given only 
a low cortisol with our patient’s history. As it is difficult to draw any 
conclusions about an ACTH level drawn after steroid treatment, it 
could have delayed true diagnosis significantly and subsequent treat-
ment for our patient. This case illustrated the importance of keeping 
a broad differential diagnosis when evaluating complex oncologic 
patients who are found to have adrenal insufficiency.
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